Latest Profitability News

Staude Capital Global Value Fund Limited reported a 21% increase in net profit after tax for FY2025, driven by strong portfolio returns and a successful discount capture strategy. The company also declared a fully franked final dividend of 3.3 cents per share and completed a $16.9 million wholesale placement.

MedAdvisor reported a 36% revenue drop in FY25, driven by US health program setbacks, and sold its ANZ business to focus on restructuring its US operations.

Bathurst Resources reports a dip in FY25 earnings due to lower coal prices and operational challenges but pushes forward with key development projects Buller and Tenas, targeting production growth from FY29.

MedAdvisor Limited reported a staggering $60.2 million loss for FY25, driven by operational challenges and asset impairments, while divesting its ANZ business and becoming debt-free.

Jayride Group Limited revealed a 55.5% plunge in revenue to $2.42 million for the fiscal year ending June 2025, alongside a reduced net loss of $5.7 million, signaling some financial stabilization despite ongoing challenges.

4DMedical Limited reported a 56% jump in FY2025 operating revenue driven by SaaS growth, while narrowing its net loss to $30.1 million. The company also secured $13.9 million in capital and a $10 million funding facility to accelerate product commercialisation.

Bubs Australia Limited reports a striking turnaround in FY25 with revenue up 29% to $102.5 million and net profit soaring 124% to $5.17 million, driven by strong US and China growth. The company awaits permanent FDA approval, a pivotal factor for its future trajectory.

Immuron Ltd reported a robust 49% increase in FY25 global sales, driven by strong Travelan® growth, while gearing up for a ProIBS launch and pivotal FDA meetings in 2025-26.

Gale Pacific’s FY25 results reveal resilience amid US market challenges, with growth in Australia and the Middle East offsetting tariff impacts and prompting a major US operating restructure.

GALE Pacific reported a slight revenue dip and a net loss in FY25, driven by US market challenges including tariffs and weak consumer demand. The company is now overhauling its US operations and diversifying manufacturing to restore profitability.

Immuron Limited reported a strong 48.6% revenue increase driven by Travelan sales in Australia and North America, yet still recorded a $5.25 million net loss for FY25. The company’s cash reserves fell sharply, prompting a post-year capital raise.

EPX Limited reported a robust 17% increase in revenue for FY2025, driven by a surge in recurring revenue and strategic expansion into industrial sectors following the Coda Cloud acquisition.